Passage Bio Q3 net loss $7.7M; cash runway into 1Q 2027; FTD trial enrollment ongoing

Passage BIO, Inc.

2025-Q3 EPS reported -$10.26

Cash and marketable securities $52.8M as of Sep 30, 2025; expected to fund operations into 1Q 2027.
Net loss narrowed to $7.7M ($2.44 per share) vs $19.3M ($6.15) in Q3 2024; R&D and G&A expenses declined.
Enrolling Cohort 3 (FTD-GRN) and Cohort 4 (FTD-C9orf72) in upliFT-D study; interim data expected in 1H 2026.
Aligned with FDA on analytical comparability plan for suspension-based PBFT02 manufacturing process.
On track for FDA feedback on FTD-GRN registrational trial design in 1H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.